ArticleOncology research2018
MicroRNA-433 Represses Proliferation and Invasion of Colon Cancer Cells by Targeting Homeobox A1.
Article in Oncology research, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
7 citing papers in PubMed, 1 synthesis or guideline pooled it.
- A Systematic Review onInternational journal of molecular sciences · 2021Pooled it
- The role of HOXA1 in cancer and targeted therapy.Medical oncology (Northwood, London, England) · 2025Review
- The role of MiRNA-433 in malignant tumors of digestive tract as tumor suppressor.Cancer reports (Hoboken, N.J.) · 2022Review
- MALAT1-miRNAs network regulate thymidylate synthase and affect 5FU-based chemotherapy.Molecular medicine (Cambridge, Mass.) · 2022Review
- The epigenetic silencing of microRNA-433 facilitates the malignant phenotypes of non-small cell lung cancer by targeting CREB1.American journal of translational research · 2021Article
- miRNA Regulation of Glutathione Homeostasis in Cancer Initiation, Progression and Therapy Resistance.MicroRNA (Shariqah, United Arab Emirates) · 2020Review
- circEIF4G2 modulates the malignant features of cervical cancer via the miR‑218/HOXA1 pathway.Molecular medicine reports · 2019Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The aberrant expression of miR-433 has been validated in some types of cancers. However, the expression profile and the biological function of miR-433 on colon cancer are still elusive. This study was designed to investigate the function of miR-433 on the proliferation and invasion of colon cancer cells. We detected the expression of miR-433 in colon cancer tissues, adjacent normal tissues, and cell lines. CCK8 and Transwell assays were performed to explore the impact of miR-433 on colon cancer cell proliferation and invasion. The luciferase reporter assay was applied to identify the direct target of miR-433. The results demonstrated that miR-433 was downregulated in colon cancer tissues and cell lines when compared with the control. Overexpression of miR-433 significantly suppressed the ability of colon cancer cell proliferation and invasion, whereas knockdown of miR-433 remarkably enhanced cell proliferation and invasion. Homeobox A1 (HOXA1) was identified as a target of miR-433, and it mediated the functions of miR-433 on colon cancer cells. To conclude, we revealed that miR-433 was downregulated in colon cancer, and it inhibited colon cancer cell proliferation and invasion by directly targeting HOXA1.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.